Gastric mucosa-associated lymphoid tissue lymphoma

Summary

Gastric mucosa-associated lymphoid tissue lymphoma (MONDO:0006226) is a cancer and 6 clinical trials. Top therapeutic interventions include metronidazole, nemtabrutinib, and orelabrutinib. A subtype of spleen cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 6

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	gastric mucosa-associated lymphoid tissue lymphoma
Mondo ID	MONDO:0006226
EFO	EFO:1000274
NCIT	C5266
UMLS	C1333782
MedGen	232547
GARD	0024340
Anatomy (UBERON)	UBERON:0000945
Is cancer (heuristic)	yes

Also known as: gastric MALT lymphoma · gastric MALToma · gastric mucosa-associated lymphoid tissue lymphoma · MALT lymphoma of stomach · MALT lymphoma of the stomach · MALToma of stomach · MALToma of the stomach · primary gastric B-cell MALT lymphoma · primary gastric MALT lymphoma · primary MALT lymphoma of stomach · primary MALT lymphoma of the stomach · stomach MALT lymphoma

Disease family

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › immune system cancer › lymphatic system cancer › spleen cancer › gastric mucosa-associated lymphoid tissue lymphoma

Related subtypes (4): spleen angiosarcoma, splenic manifestation of leukemia, small intestinal mucosa-associated lymphoid tissue lymphoma, tonsillar lymphoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 6.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	3
Not specified	2
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06228963	PHASE2	RECRUITING	Orelabrutinib in the Treatment of HP-positive Gastric MALT Lymphoma
NCT07144657	PHASE2	NOT_YET_RECRUITING	Prospective Study of Frontline Antibiotics Therapy in the Treatment of Early-stage HP-negative Gastric MALT Lymphoma
NCT07583810	PHASE2	NOT_YET_RECRUITING	Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma
NCT03680586	EARLY_PHASE1	ACTIVE_NOT_RECRUITING	Ultra Low-Dose Radiation Therapy in Treating Patients With Stage I-IV Stomach MALT Lymphoma
NCT06454149	Not specified	RECRUITING	Cohort Study for Gastric MALT Lymphoma
NCT00327132	Not specified	COMPLETED	Prospective Study of First-line Antibiotic Therapy for Early-stage Gastric MALT Lymphoma for Treatment Outcome

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
METRONIDAZOLE	4	1
NEMTABRUTINIB	3	1
ORELABRUTINIB	3	1